An Open Label, Non-comparative, Multicenter Study to Assess the Pharmacokinetics, Safety and Efficacy of Tafenoquine (SB-252263, WR238605) in the Treatment of Pediatric Subjects With Plasmodium Vivax Malaria

This is a prospective, open-label, multicenter, non-comparative, single arm study of
pediatric subjects with Plasmodium vivax (P. vivax) malaria, aged 6 months to <16 years of
age. A total of 60 subjects will be enrolled. Potential subjects who are slide-positive for
P. vivax will be started by the site on chloroquine (CQ) per local/national guidelines. Sites
will have up to 48 hours to obtain consent. Once full consent is provided, all subjects will
be screened and, if eligible, receive Tafenoquine (TQ), given as a single dose on Day 1. All
study medication should be taken with food. After the treatment period, subjects will attend
up to 7 follow-up visits through Day 120 (Days 3, 8, 15, 29, 60, 90 and 120). The main cohort
will consist of subjects aged >=2 years to <16 years with no restriction on gender. Subjects
will be dosed according to four weight bands. Within the total of 60 enrolled pediatric
subjects, a second cohort of up to 6 infants aged >=6 months to <2 years (weighing >=5
kilogram [kg]) will be recruited following completion of a planned first interim analysis. An
interim analysis will be conducted once sufficient data from 16 subjects is available to
assess pharmacokinetic (PK) and safety parameters. If needed, a second interim analysis will
be conducted after a total of 32 subjects have enrolled. The primary objective of this PK
bridging study is to adequately characterize the systemic TQ exposure in the pediatric
population in order to identify appropriate doses that achieve a similar exposure to that of
the TQ adult dose of 300 milligram (mg).